Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

NCT04322227 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Study termination due to efficacy results of another study

Conditions

Parkinson Disease
Healthy

Interventions

DRUG: Foliglurax 10 mg (treatment A)
DRUG: Foliglurax 30 mg (treatment B)
DRUG: Placebo (treatment C)

Sponsor

H. Lundbeck A/S